Jian D Kang

US Patent:

20230089220, Mar 23, 2023

Filed:

Sep 22, 2021

Appl. No.:

17/448499

Inventors:

- San Diego CA, US
Kyle David Holland - San Diego CA, US
Jian Kang - San Diego CA, US
Aleksandar Miodrag Tasic - San Diego CA, US
Chih-Fan Liao - San Diego CA, US
Yingying Li - San Diego CA, US
Lai Kan Leung - San Marcos CA, US
Chiewcharn Narathong - Laguna Niguel CA, US

International Classification:

H04B 1/16

Abstract:

Embodiments of this disclosure may include a receiver with a reconfigurable processing path for different signal conditions. Such a receiver may reconfigure between a mixer-first configuration and an amplifier-first configuration. In the mixer-first configuration, an RF input signal is not passed through an LNA for amplification before processing the RF input signal for downconversion to baseband and eventual extraction of the information in the signal. In the amplifier-first configuration, an RF input signal is passed through an LNA for amplification before processing the RF input signal for downconversion to baseband and eventual extraction of the information in the signal. Reconfiguring the receiver between mixer-first and amplifier-first configurations may be performed based on detection of jammer signals and/or measurement of signal-to-noise ratio (SNR).

US Patent:

20230023070, Jan 26, 2023

Filed:

Dec 1, 2020

Appl. No.:

17/781680

Inventors:

- Summit NJ, US
Hsiling Chiu - Livingston NJ, US
Patrick Hagner - Sparta NJ, US
Jian Kang - Warren NJ, US
Anjan Thakurta - Basking Ridge NJ, US

International Classification:

A61K 31/4035
A61K 38/55
A61P 35/00

Abstract:

Provided herein are methods of treating and/or managing cancer, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. Additionally, provided herein are methods of treating and/or managing cancer, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with a second agent selected from the group consisting of an anti-CD20 antibody, an HDAC inhibitor, a proteasome inhibitor, an anti-CD38 antibody, an anti-SLAMF7 antibody, a nuclear export inhibitor, a BCL-2 inhibitor, and an immune checkpoint inhibitor. Also provided herein are combination therapies for treating and/or managing cancer, which further comprise dexamethasone as a third agent.